Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of Type-1 diabetes

Pharmacological Research

Volumn 66, Issue 3, 2012, Pages 269-275

  Yousif, Mariam H M ^a   Dhaunsi, Gursev S ^a   Makki, Batoul M ^a   Qabazard, Bedour A ^b   Akhtar, Saghir ^a   Benter, Ibrahim F ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Angiotensin (1 7); Diabetes; Heart; Ischemia reperfusion; NADPH oxidase

Indexed keywords

ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DX 600; ENDOTHELIN 1; INDOMETACIN; LOSARTAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LOCALIZATION; HEART; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STREPTOZOCIN DIABETES; TISSUE DISTRIBUTION;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; CAPTOPRIL; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HYPERGLYCEMIA; KIDNEY; LOSARTAN; MALE; NADPH OXIDASE; PEPTIDE FRAGMENTS; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; PROSTAGLANDINS; PROTO-ONCOGENE PROTEINS; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; REPERFUSION INJURY;

EID: 84864277076     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.05.001     Document Type: Article

References (31)

1. S.P. Laing, A.J. Swerdlow, S.D. Slater, A.C. Burden, A. Morris, and N.R. Waugh Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes Diabemtologia 46 2003 760 765 (Pubitemid 36831403)
2. F. Giacco, and M. Brownlee Oxidative stress and diabetic complications Circulation Research 107 2010 1058 1070
3. R.M. Touyz, A.M. Briones, M. Sedeek, D. Burger, and A.C. Montezano NOX isoforms and reactive oxygen species in vascular health Molecular Interventions 11 2011 27 35
4. M. Donoghue, F. Hsieh, E. Baronas, K. Godbout, M. Gosselin, and N. Stagliano A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Circulation Research 87 2000 E1 E9
5. J.L. Guy, D.W. Lambert, A.J. Turner, and K.E. Porter Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts Experimental Physiology 93 2008 579 588 (Pubitemid 351595051)
6. I.F. Benter, C.M. Ferrario, M. Morris, and D.I. Diz Antihypertensive actions of Angiotensin-(1-7) in spontaneously hypertensive rats American Journal of Physiology 269 1995 H313 H319
7. E.A. Tallant, C.M. Ferrario, and P.E. Gallagher Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the Mas receptor American Journal of Physiology. Heart and Circulatory Physiology 289 2005 H1560 H1566
8. S. Tesanovic, A. Vinh, T.A. Gaspari, D. Casley, and R.E. Widdop Vasoprotective and atheroprotective effects of Angiotensin-(1-7) in apolipoprotein E-deficient mice Arteriosclerosis Thrombosis and Vascular Biology 30 2010 1606 1613
9. R.A. Fraga-Silva, F.P. Costa-Fraga, F.B. De Sousa, N. Alenina, M. Bader, and R.A. Santos An orally active formulation of Angiotensin-(1-7) produces an antithrombotic effect Clinics 66 2011 837 841
10. R.A. Santos, A.C. Simoes e Silva, C. Maric, D.M. Silva, R.P. Machado, and I. de Buhr Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas Proceedings of the National Academy of Sciences of the United States of America 100 2003 8258 8263 (Pubitemid 36842532)
11. C.M. Ferrario, S. Ahmad, J. Joyner, and J. Varagic Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7) Advances in Pharmacology 59 2010 197 233
12. I.F. Benter, M.H. Yousif, J.T. Anim, C. Cojocel, and D.I. Diz Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME American Journal of Physiology. Heart and Circulatory Physiology 290 2006 H684 H691
13. I.F. Benter, M.H. Yousif, C. Cojocel, M. Al-Maghrebi, and D.I. Diz Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction American Journal of Physiology. Heart and circulatory physiology 292 2007 H666 H672
14. L.A. Rabelo, N. Alenina, and M. Bader ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease Hypertension Research 34 2011 154 160
15. L. Huang, D.J. Sexton, K. Skogerson, M. Devlin, R. Smith, and I. Sanyal Novel peptide inhibitors of angiotensin-converting enzyme, 2 Journal of Biological Chemistry 278 2003 15532 15540 (Pubitemid 36799660)
16. K.B. Pedersen, S. Sriramula, K.H. Chhabra, H. Xia, and E. Lazartigues Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 301 2011 R1293 R1299
17. I.F. Benter, M.H. Yousif, F.M. Al-Saleh, R. Raghupathy, M.C. Chappell, and D.I. Diz Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with ng-nitro-l-arginine methyl ester Journal of Cardiovascular Pharmacology 57 2011 559 567
18. G.S. Dhaunsi, M.H. Yousif, S. Akhtar, M.C. Chappell, D.I. Diz, and I.F. Benter Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities European Journal of Pharmacology 638 2010 108 114
19. C.X. Liu, Q. Hu, Y. Wang, W. Zhang, Z.Y. Ma, and J.B. Feng Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition Molecular Medicine 17 2011 59 69
20. B. Dong, Q.T. Yu, H.Y. Dai, Y.Y. Gao, Z.L. Zhou, and L. Zhang Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy Journal of the American College of Cardiology 59 2012 739 747
21. M.C. Thomas, R.J. Pickering, D. Tsorotes, A. Koitka, K. Sheehy, and S. Bernardi Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse Circulation Research 107 2010 888 897
22. C. Tikellis, K. Bialkowski, J. Pete, K. Sheehy, Q. Su, and C. Johnston ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes Diabetes 57 2008 1018 1025
23. M.J. Soler, J. Wysocki, M. Ye, J. Lloveras, Y. Kanwar, and D. Batlle ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice Kidney International 72 2007 614 623 (Pubitemid 47312795)
24. M. Ye, J. Wysocki, J. William, M.J. Soler, I. Cokic, and D. Batlle Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes Journal of the American Society of Nephrology 17 2006 3067 3075 (Pubitemid 44707767)
25. A. Ergul Endothelin-1 and diabetic complications: focus on the vasculature Pharmacological Research 63 2011 477 482
26. A.K. Banes-Berceli, S. Ogobi, A. Tawfik, B. Patel, A. Shirley, and D.M. Pollock Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NADPH oxidase-derived reactive oxygen species Vascular Pharmacology 43 2005 310 319 (Pubitemid 41608754)
27. I.F. Benter, M.H. Yousif, G.S. Dhaunsi, J. Kaur, M.C. Chappell, and D.I. Diz Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats American Journal of Nephrology 28 2008 25 33 (Pubitemid 350126490)
28. S.N. Iyer, C.M. Ferrario, and M.C. Chappell Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system Hypertension 31 1998 356 361
29. P. Ruggenenti, P. Cravedi, and G. Remuzzi The RAAS in the pathogenesis and treatment of diabetic nephropathy Nature Reviews Nephrology 6 2010 319 330
30. M.A. Munger Polypharmacy and combination therapy in the management of hypertension in elderly patients with co-morbid diabetes mellitus Drugs and Aging 27 2010 871 883
31. A. Soro-Paavonen, D. Gordin, C. Forsblom, M. Rosengard-Barlund, J. Waden, and L. Thorn Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications Journal of Hypertension 30 2012 375 383